BioCryst Pharmaceuticals, Inc. (BCRX)
9.67
+0.12
(+1.26%)
USD |
NASDAQ |
Aug 24, 16:00
9.77
+0.10
(+1.03%)
After-Hours: 20:00
BioCryst Pharmaceuticals Enterprise Value : 2.921B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 2.921B |
| August 20, 2026 | 2.949B |
| August 19, 2026 | 3.054B |
| August 18, 2026 | 2.960B |
| August 17, 2026 | 3.021B |
| August 14, 2026 | 2.970B |
| August 13, 2026 | 2.988B |
| August 12, 2026 | 3.187B |
| August 11, 2026 | 3.123B |
| August 10, 2026 | 2.995B |
| August 07, 2026 | 2.878B |
| August 06, 2026 | 2.858B |
| August 05, 2026 | 2.799B |
| August 04, 2026 | 2.786B |
| August 03, 2026 | 2.732B |
| July 31, 2026 | 2.776B |
| July 30, 2026 | 2.842B |
| July 29, 2026 | 2.916B |
| July 28, 2026 | 2.970B |
| July 27, 2026 | 2.929B |
| July 24, 2026 | 2.868B |
| July 23, 2026 | 2.878B |
| July 22, 2026 | 2.911B |
| July 21, 2026 | 2.888B |
| July 20, 2026 | 2.809B |
| Date | Value |
|---|---|
| July 17, 2026 | 2.855B |
| July 16, 2026 | 2.808B |
| July 15, 2026 | 2.886B |
| July 14, 2026 | 2.970B |
| July 13, 2026 | 3.013B |
| July 10, 2026 | 3.151B |
| July 09, 2026 | 3.220B |
| July 08, 2026 | 3.320B |
| July 07, 2026 | 3.289B |
| July 06, 2026 | 3.080B |
| July 02, 2026 | 2.995B |
| July 01, 2026 | 2.947B |
| June 30, 2026 | 3.036B |
| June 29, 2026 | 3.045B |
| June 26, 2026 | 3.144B |
| June 25, 2026 | 3.134B |
| June 24, 2026 | 3.159B |
| June 23, 2026 | 2.984B |
| June 22, 2026 | 2.941B |
| June 18, 2026 | 2.902B |
| June 17, 2026 | 2.892B |
| June 16, 2026 | 2.885B |
| June 15, 2026 | 2.920B |
| June 12, 2026 | 2.829B |
| June 11, 2026 | 2.778B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Amgen, Inc. | 280.82B |
| Vertex Pharmaceuticals, Inc. | 132.96B |
| Agenus, Inc. | 609.42M |
| Anika Therapeutics, Inc. | 278.32M |
| Imunon, Inc. | 8.633M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 78.40M |
| Revenue (Quarterly) | 218.25M |
| Total Expenses (Quarterly) | 139.86M |
| EPS Diluted (Quarterly) | 0.2957 |
| Gross Profit Margin (Quarterly) | 98.01% |
| Profit Margin (Quarterly) | 35.92% |
| Earnings Yield | -15.55% |
| Operating Earnings Yield | 16.81% |
| Normalized Earnings Yield | 5.775 |